Icos Corporation

Omeros Corporation

Euroscreen S.a. Icos Corporation

University of Leicester

Euroscreen S.a.

Patrick W Gray

Larry W Tjoelker

Lawrence S Cousens

Cheryl L Wilder

Hai Le Trong

Christine D Eberhardt

Ronald Godiska

Vicki Louise Schweickart

Carol J Raport

David H Chantry

Gregory A Demopulos

Neil S Cutshall

Merl F Hoekstra

George A Gaitanaris

John E Bergmann

Hongkui Zeng

John Hohmann

Vincent A Florio

Rene Onrust

Michael C Deeley

Thomas Dudler

Hans-Wilhelm Schwaeble

Munehisa Yabuki

W Jason Cummings

Vicki L Schweickart

Vicki L Schwickart

In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid sequence of at least one bioactive peptide of interest into (i) at least one of CDR-H1, CDR-H2 or CDR-H3 of a heavy chain variable region comprising one or more chicken framework regions and/or (ii) at least one of CDR-L1, CDR-L2 or CDR-L3 of the light chain variable region comprising one or more chicken framework regions, and (b) determining whether the antibody has substantially the same biological activity as the bioactive peptide.

Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same

A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

Use of PDE7 inhibitors for the treatment of movement disorders

The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.

Method of screening for modulators of HIV infection

The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C&#x2014;C chemokine designated 'Macrophage Derived Chemokine' (MDC), and polypeptide fragments and analogs thereof. Also provided are materials and methods for the recombinant or synthetic production of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity.

Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof

Antibodies to chemokine receptor 88C

The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C&mdash;C chemokine designated MDC. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein.

Polynucleotides encoding macrophage derived chemokine

The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.

Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same

The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.

Methods of identifying agents that modulate the binding between MDC and an MDC receptor

The present invention provides chitin-binding fragments of human chitinase, fragment analogs, purified and isolated polynucleotide sequences encoding such fragments and analogs, and materials and methods for the recombinant production of human chitinase fragment products which are expected to be useful as in products for detecting chitin, binding chitin, and treating fungal infections or for development of products useful for treating the same.

Chitinase chitin-binding fragments

The present invention provides purified and isolated polynucleotide sequences encoding human chitinase. Also provided are materials and methods for the recombinant production of human chitinase products which are expected to be useful as products for treating fungal infections or for development of products useful for treating the same.

Chitinase materials and methods

DNA sequences encoding seven novel seven transmembrane receptors and variants thereof are disclosed as well as materials and methods for production of the same by recombinant techniques. Antibody substances specific for each of the seven transmembrane receptors are disclosed as useful for the modulation of the ligand/receptor binding reactions of the receptors.

Seven transmembrane receptors

The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated MDC. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein.

Macrophage derived chemokine

Chemokine receptor 88-C

The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, and other inflammatory conditions.

Growing community of inventors

Seattle, WA, United States of America

Patrick W Gray